Dr. Mahmood has more than 25 years of experience in clinical pharmacology with the FDA. He worked both in the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER). During this period, Dr. Mahmood worked on neurological products, therapeutic proteins (antibodies and non-antibodies), coagulation factors (hemophilia), immunoglobulins, and cell and gene therapy. Dr. Mahmood helped in establishing a robust clinical pharmacology program in the Office of Blood Review and Research and the Office of Tissue & Advanced Therapies (OTAT), CBER. In CBER, he led a team of clinical and pre-clinical pharmacologists for two years. Dr. Mahmood was a member of several working groups in CDER and CBER which wrote guidances for the pharmaceutical industry. He received three research grants from CDER for conducting research in the area of anti-epilepsy drugs, pediatric clinical pharmacology, and drug-drug interaction. At the FDA, besides his regular IND, BLA, and NDA review duties, Dr. Mahmood was also involved with clinical pharmacology research (both small and large molecules) and published more than 100 research papers in peer-reviewed scientific journals. His research mainly focused on allometric scaling, modeling, sparse sampling, and pediatric drug development. Dr. Mahmood has also edited and written several scientific books.